Publication number: 20060100254
Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in Claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
Type:
Application
Filed:
October 5, 2005
Publication date:
May 11, 2006
Applicant:
Boehringer Ingelheim International GmbH
Inventors:
Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
Publication number: 20050085522
Abstract: A compound of formula I or of tautomeric formula II wherein: R1 and R5 are each independently H, F, Cl, Br, CH2F, CHF2, CF3, Me, or OMe; R2 and R4 are each independently H, a branched C3-6-alkyl, F, Cl, Br, CH2F, CHF2, CF3 or Me, wherein at least one of the groups R2 or R4 is a branched C3-6-alkyl; and R3 is H, F, Cl, Br, CH2F, CHF2, CF3 or Me, or a pharmacologically acceptable salt thereof, pharmaceutical compositions containing these compounds, and their use in treating urinary incontinence or a bladder disease.
Type:
Application
Filed:
December 7, 2004
Publication date:
April 21, 2005
Applicant:
Boehringer Ingelheim International GmbH
Inventors:
Pascale Pouzet, Franz Esser, Matthias Hoffmann, Hisato Kitagawa, Kenji Sakai, Ikunobu Muramatsu